cmv/adv /ebv/bkv specific t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03159364)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- BK polyomavirusImmunity, passive
BK polyomavirus immunity, passive
- Human herpesvirus 4Immunity, passive
Human herpesvirus 4 immunity, passive
- Human adenovirus type 2Immunity, passive
Human adenovirus type 2 immunity, passive
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cmv/ebv/adv/bkv specific ctls
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03594981 | Phase 1/Phase 2 (Phase 2) | Jan 24, 2018 | Georgetown University, University of Texas at Houston |
| NCT03159364 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | Shenzhen Geno-Immune Medical Institute |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1